Intensity Therapeutics will announce its financial results for Q3 2026 before market open on November 5, 2026, followed by a conference call at 8 AM ET to discuss results and corporate updates. The company is developing INT230-6, a novel intratumoral cancer therapy designed to kill tumors and stimulate immune response without immunosuppression. Intensity is advancing multiple clinical trials, including a Phase 3 study in soft tissue sarcoma and Phase 2/3 trials in breast cancer. Investors can access the live webcast and replay for detailed insights into the company’s progress and future plans.
Intensity Therapeutics' upcoming Q3 2026 financial results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 30, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 75 rose and 70 fell. Notable movers include Regeneron Pharmaceuticals Inc (REGN) at USD 875.00 with a 1-day change of +6.87% and a typical hold time of 108 days, BrightSpring Health Services Inc. (BTSG) at USD 64.15 with a +6.53% change and 90% buy order activity, and Twist Bioscience Corp (TWST) at USD 162.37 with a -6.39% change and 64% buy order activity.
FreightCar America disclosed on October 19, 2026, that it removed 1,285 railcars from its backlog after a customer was unlikely to fulfill contractual obligations, causing its stock to drop 31.4% to $4.02. This sharp decline has led Glancy Prongay Wo...
FirstCash Holdings, Inc. shares fell 14.75% following the October 22, 2026 disclosure of its third quarter financial results, which showed a 28% year-over-year decline in operating income for its American First Finance segment to $33 million. The com...
The global screw compressors market is projected to grow from $13.97 billion in 2026 to $18.38 billion by 2031, at a CAGR of 5.66%. Growth is fueled by rising industrial automation, energy-efficiency regulations, and demand in manufacturing, oil and ...
Enova International's stock fell 23.43% after the company withdrew its application to acquire Grasshopper Bancorp and become a bank holding company. The withdrawal was due to unclear regulatory standards and political pressures cited by Enova. This s...
The global dialysis machines market is forecasted to grow from $17.89 billion in 2026 to $31.54 billion by 2035, at a CAGR of 6.5%. Growth is fueled by rising chronic kidney disease cases, expanding dialysis infrastructure, and innovations like home ...
